We hypothesized that endocan, ET-1, and NT-proBNP may play a role in endothelial dysfunction in IgAN patients because endothelial injury could be a key factor in the progression of CKD [38], and we should use them as new biomarkers for progressive cases. This evidence concerns the gene EDN1 and endothelial dysfunction.